Abbott Laboratories (ABT) Financials

$132.41 +0.41 (+0.31%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$132.52 +0.11 (+0.09%)

As of 08/22/2025 07:46 PM Eastern

Annual Income Statements for Abbott Laboratories

This table shows Abbott Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	2,284	4,423	1,400	477	2,368	3,687	4,495	7,071	6,933	5,723	13,402
Consolidated Net Income / (Loss)	2,284	4,423	1,400	477	2,368	3,687	4,495	7,071	6,933	5,723	13,402
Net Income / (Loss) Continuing Operations	1,721	2,606	1,063	353	2,334	3,687	4,471	7,071	6,933	5,723	13,402
Total Pre-Tax Income	2,518	3,183	1,413	2,231	2,873	4,077	4,968	8,211	8,306	6,664	7,013
Total Operating Income	2,599	2,867	3,026	1,564	3,650	4,532	5,357	8,425	8,362	6,478	6,825
Total Gross Profit	11,029	11,658	11,759	14,981	17,872	18,673	19,605	24,538	24,511	22,134	23,244
Total Revenue	20,247	20,405	20,853	27,390	30,578	31,904	34,608	43,075	43,653	40,109	41,950
Operating Revenue	20,247	20,405	20,853	27,390	30,578	31,904	34,608	43,075	43,653	40,109	41,950
Total Cost of Revenue	9,218	8,747	9,094	12,409	12,706	13,231	15,003	18,537	19,142	17,975	18,706
Operating Cost of Revenue	9,218	8,747	9,094	12,409	12,706	13,231	15,003	18,537	19,142	17,975	18,706
Total Operating Expenses	8,430	8,791	8,733	13,417	14,222	14,141	14,248	16,113	16,149	15,656	16,419
Selling, General & Admin Expense	6,530	6,785	6,736	9,182	9,744	11,701	9,696	11,324	11,248	10,949	11,697
Research & Development Expense	1,345	1,405	1,447	2,260	2,300	2,440	2,420	2,742	2,888	2,741	2,844
Amortization Expense	555	601	550	1,975	2,178	-	2,132	2,047	2,013	1,966	1,878
Total Other Income / (Expense), net	-81	316	-1,613	667	-777	-455	-389	-214	-56	186	188
Interest Expense	168	163	431	904	993	733	546	533	558	637	559
Interest & Investment Income	77	105	99	124	105	94	46	43	183	385	344
Other Income / (Expense), net	10	374	-1,281	1,447	111	184	111	276	319	438	403
Income Tax Expense	797	577	350	1,878	539	390	497	1,140	1,373	941	-6,389
Basic Earnings per Share	$1.50	$2.94	$0.94	$0.27	$1.34	$2.07	$2.52	$3.97	$3.94	$3.28	$7.67
Weighted Average Basic Shares Outstanding	1.52B	1.50B	1.48B	1.74B	1.76B	1.77B	1.77B	1.78B	1.75B	1.74B	1.74B
Diluted Earnings per Share	$1.49	$2.92	$0.94	$0.27	$1.33	$2.06	$2.50	$3.94	$3.91	$3.26	$7.64
Weighted Average Diluted Shares Outstanding	1.53B	1.51B	1.48B	1.75B	1.77B	1.78B	1.79B	1.79B	1.76B	1.75B	1.75B
Weighted Average Basic & Diluted Shares Outstanding	1.52B	1.50B	1.73B	1.75B	1.77B	1.76B	1.77B	1.76B	1.74B	1.74B	1.73B
Cash Dividends to Common per Share	-	-	-	-	-	-	-	-	$1.92	$2.08	$2.24

This table shows Abbott Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	1,033	1,318	1,375	1,436	1,594	1,225	1,302	1,646	9,229	1,325	1,779
Consolidated Net Income / (Loss)	1,033	1,318	1,375	1,436	1,594	1,225	1,302	1,646	9,229	1,325	1,779
Net Income / (Loss) Continuing Operations	1,033	1,318	1,375	1,436	1,594	1,225	1,302	1,646	9,229	1,325	1,779
Total Pre-Tax Income	1,320	1,562	1,636	1,671	1,795	1,436	1,607	1,940	2,030	1,778	2,150
Total Operating Income	1,304	1,509	1,542	1,647	1,780	1,386	1,669	1,859	1,911	1,693	2,052
Total Gross Profit	5,498	5,416	5,495	5,538	5,685	5,501	5,774	5,937	6,032	5,890	6,288
Total Revenue	10,091	9,747	9,978	10,143	10,241	9,964	10,377	10,635	10,974	10,358	11,142
Operating Revenue	10,091	9,747	9,978	10,143	10,241	9,964	10,377	10,635	10,974	10,358	11,142
Total Cost of Revenue	4,593	4,331	4,483	4,605	4,556	4,463	4,603	4,698	4,942	4,468	4,854
Operating Cost of Revenue	4,593	4,331	4,483	4,605	4,556	4,463	4,603	4,698	4,942	4,468	4,854
Total Operating Expenses	4,194	3,907	3,953	3,891	3,905	4,115	4,105	4,078	4,121	4,197	4,236
Selling, General & Admin Expense	2,973	2,762	2,740	2,723	2,724	2,959	2,936	2,895	2,907	3,061	3,091
Research & Development Expense	725	654	715	672	700	684	698	713	749	716	725
Amortization Expense	496	491	498	496	481	472	471	470	465	420	420
Total Other Income / (Expense), net	16	53	94	24	15	50	-62	81	119	85	98
Interest Expense	154	153	159	166	159	141	140	142	136	131	121
Interest & Investment Income	88	101	98	97	89	80	82	91	91	82	71
Other Income / (Expense), net	82	105	155	93	85	111	-4.00	132	164	134	148
Income Tax Expense	287	244	261	235	201	211	305	294	-7,199	453	371
Basic Earnings per Share	$0.59	$0.75	$0.79	$0.82	$0.92	$0.70	$0.74	$0.94	$5.29	$0.76	$1.02
Weighted Average Basic Shares Outstanding	1.75B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B
Diluted Earnings per Share	$0.59	$0.75	$0.78	$0.82	$0.91	$0.70	$0.74	$0.94	$5.26	$0.76	$1.01
Weighted Average Diluted Shares Outstanding	1.76B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B
Weighted Average Basic & Diluted Shares Outstanding	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.73B	1.73B	1.74B	1.74B
Cash Dividends to Common per Share	-	-	-	$0.51	-	$0.55	$0.55	$0.55	-	$0.59	$0.59

This table details how cash moves in and out of Abbott Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	588	938	13,619	-9,329	-5,447	16	2,978	2,961	83	-2,986	720
Net Cash From Operating Activities	3,675	2,966	3,203	5,570	6,300	6,136	7,901	10,533	9,581	7,261	8,558
Net Cash From Continuing Operating Activities	3,675	2,966	3,203	5,570	6,300	6,136	7,901	10,533	9,581	7,261	8,558
Net Income / (Loss) Continuing Operations	2,284	4,423	1,400	477	2,368	3,687	4,495	7,071	6,933	5,723	13,402
Consolidated Net Income / (Loss)	2,284	4,423	1,400	477	2,368	3,687	4,495	7,071	6,933	5,723	13,402
Depreciation Expense	918	871	803	1,046	1,100	1,078	1,195	1,491	1,254	1,277	1,340
Amortization Expense	630	601	715	2,887	2,210	1,936	2,132	2,047	2,013	1,966	1,878
Non-Cash Adjustments To Reconcile Net Income	333	-2,773	1,798	-755	770	766	971	695	900	770	1,155
Changes in Operating Assets and Liabilities, net	-490	-156	-1,513	1,915	-148	-1,331	-892	-771	-1,519	-2,475	-9,217
Net Cash From Investing Activities	-202	406	-248	-9,618	-1,356	-1,815	-2,215	-2,008	-1,740	-3,133	-2,338
Net Cash From Continuing Investing Activities	-202	406	-248	-9,618	-1,356	-1,815	-2,215	-2,008	-1,740	-3,133	-2,338
Purchase of Property, Plant & Equipment	-1,077	-1,110	-1,121	-1,135	-1,394	-1,638	-2,177	-1,885	-1,777	-2,202	-2,207
Acquisitions	-3,317	-235	-80	-17,183	-54	-170	-42	-187	0.00	-877	0.00
Purchase of Investments	-1,507	-4,933	-2,823	-210	-131	-103	-83	-173	-185	-159	-169
Divestitures	5.00	230	25	6,042	48	48	58	134	48	40	1.00
Sale and/or Maturity of Investments	5,624	6,402	3,709	2,833	73	21	10	77	152	43	28
Other Investing Activities, net	70	52	42	35	102	27	19	26	22	22	9.00
Net Cash From Financing Activities	-2,742	-2,236	11,147	-5,281	-10,391	-4,289	-2,779	-5,494	-7,636	-7,091	-5,404
Net Cash From Continuing Financing Activities	-2,742	-2,236	11,147	-5,281	-10,391	-4,289	-2,779	-5,494	-7,636	-7,091	-5,404
Repayment of Debt	766	-1,338	-1,949	-9,684	-12,459	-3,441	-1,342	-252	-706	-2,477	-760
Repurchase of Common Equity	-2,195	-2,237	-522	-117	-238	-718	-403	-2,299	-3,795	-1,227	-1,295
Payment of Dividends	-1,342	-1,443	-1,539	-1,849	-1,974	-2,270	-2,560	-3,202	-3,309	-3,556	-3,836
Issuance of Debt	0.00	2,485	14,934	6,742	4,009	1,842	1,281	4.00	7.00	2.00	223
Other Financing Activities, net	29	297	223	337	271	298	245	255	167	167	264
Effect of Exchange Rate Changes	-143	-198	-483	-	-	-16	71	-70	-122	-23	-96
Cash Interest Paid	146	166	181	917	845	677	549	544	563	662	604
Cash Income Taxes Paid	448	631	620	570	740	930	970	1,941	1,864	1,475	1,723

This table details how cash moves in and out of Abbott Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Change in Cash & Equivalents	288	-721	-1,326	-1,126	187	-612	703	571	58	-1,084	419
Net Cash From Operating Activities	2,326	1,143	1,203	1,877	3,038	1,025	1,960	2,705	2,868	1,417	2,047
Net Cash From Continuing Operating Activities	2,326	1,143	1,203	1,877	3,038	1,025	1,960	2,705	2,868	1,417	2,047
Net Income / (Loss) Continuing Operations	1,033	1,318	1,375	1,436	1,594	1,225	1,302	1,646	9,229	1,325	1,779
Consolidated Net Income / (Loss)	1,033	1,318	1,375	1,436	1,594	1,225	1,302	1,646	9,229	1,325	1,779
Depreciation Expense	311	315	302	328	332	333	334	331	342	336	357
Amortization Expense	496	491	498	496	481	472	471	470	465	420	420
Non-Cash Adjustments To Reconcile Net Income	330	281	132	117	240	304	141	117	593	289	142
Changes in Operating Assets and Liabilities, net	156	-1,262	-1,104	-500	391	-1,309	-288	141	-7,761	-953	-651
Net Cash From Investing Activities	-632	-462	-1,213	-634	-824	-425	-453	-594	-866	-470	-582
Net Cash From Continuing Investing Activities	-632	-462	-1,213	-634	-824	-425	-453	-594	-866	-470	-582
Purchase of Property, Plant & Equipment	-610	-380	-507	-560	-755	-398	-533	-556	-720	-484	-502
Other Investing Activities, net	8.00	4.00	1.00	15	2.00	1.00	2.00	2.00	4.00	6.00	2.00
Net Cash From Financing Activities	-1,457	-1,410	-1,289	-2,340	-2,052	-1,176	-791	-1,576	-1,861	-2,055	-1,097
Net Cash From Continuing Financing Activities	-1,457	-1,410	-1,289	-2,340	-2,052	-1,176	-791	-1,576	-1,861	-2,055	-1,097
Repayment of Debt	10	-42	11	-1,506	-940	-127	-61	42	-614	-1,037	-99
Repurchase of Common Equity	-685	-540	-426	-2.00	-259	-226	-3.00	-751	-315	-280	-6.00
Payment of Dividends	-823	-890	-890	-888	-888	-957	-961	-960	-958	-1,026	-1,029
Issuance of Debt	-	-	-	-	1.00	0.00	-	1.00	1.00	1.00	2.00
Other Financing Activities, net	41	62	15	56	34	134	13	92	25	287	35
Effect of Exchange Rate Changes	51	8.00	-	-	25	-	-13	36	-83	24	51

This table presents Abbott Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	41,207	41,247	52,666	76,250	67,173	67,887	72,548	75,196	74,438	73,214	81,414
Total Current Assets	13,556	14,155	26,776	20,147	14,632	15,667	20,441	24,239	25,224	22,670	23,656
Cash & Equivalents	4,063	5,001	18,620	9,407	3,844	3,860	6,838	9,799	9,882	6,896	7,616
Short-Term Investments	397	1,124	155	203	242	280	310	450	288	383	351
Accounts Receivable	3,586	3,418	3,248	5,249	5,182	5,425	6,414	6,487	6,218	6,565	6,925
Inventories, net	2,643	2,599	2,434	3,601	3,796	4,316	5,012	5,157	6,173	6,570	6,194
Prepaid Expenses	-	-	-	1,667	1,568	1,786	1,867	2,346	2,663	2,256	2,570
Plant, Property, & Equipment, net	5,935	5,730	5,705	7,607	7,563	8,038	9,029	8,959	9,162	10,154	10,658
Plant, Property & Equipment, gross	25,264	12,383	12,366	15,265	15,706	16,799	18,793	19,364	20,212	21,933	22,740
Accumulated Depreciation	6,697	6,653	6,661	7,658	8,143	8,761	9,764	10,405	11,050	11,779	12,082
Total Noncurrent Assets	21,716	21,362	20,185	48,496	44,978	44,182	43,078	41,998	40,052	40,390	47,100
Long-Term Investments	229	4,041	2,947	883	897	883	821	816	766	799	886
Goodwill	10,067	9,638	7,683	24,020	23,254	23,195	23,744	23,231	22,799	23,679	23,108
Intangible Assets	6,198	5,562	4,539	21,473	18,942	17,025	14,784	12,739	10,454	8,815	6,647
Noncurrent Deferred & Refundable Income Taxes	-	2,119	2,263	1,944	1,885	3,079	3,729	5,212	6,033	7,097	16,459
Total Liabilities & Shareholders' Equity	41,207	41,247	52,666	76,250	67,173	67,887	72,548	75,196	74,438	73,214	81,414
Total Liabilities	19,568	19,921	31,949	45,152	36,451	36,586	39,545	39,172	37,533	34,387	33,513
Total Current Liabilities	10,467	9,186	6,660	8,912	9,012	10,863	11,907	13,105	15,489	13,841	14,157
Short-Term Debt	4,437	3,130	1,325	714	207	1,478	220	754	2,251	1,080	1,500
Accounts Payable	1,064	1,081	1,178	2,402	2,975	3,252	3,946	4,408	4,607	4,295	4,195
Accrued Expenses	2,878	3,043	2,581	3,811	3,780	4,035	5,165	5,181	5,845	5,422	5,143
Dividends Payable	362	383	391	489	563	635	798	831	887	955	1,024
Current Deferred & Payable Income Tax Liabilities	270	430	188	309	305	226	362	306	343	492	594
Current Employee Benefit Liabilities	776	746	752	1,187	1,182	1,237	1,416	1,625	1,556	1,597	1,701
Total Noncurrent Liabilities	9,101	10,735	25,289	36,240	27,439	25,723	27,638	26,067	22,044	20,546	19,356
Long-Term Debt	3,393	5,871	20,681	27,210	19,359	16,661	18,527	17,296	14,522	13,599	12,625
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	9,030	8,080	-	-	-	-	-	6,731
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	21,639	21,326	20,717	31,098	30,722	31,301	33,003	36,024	36,905	38,827	47,901
Total Preferred & Common Equity	21,526	21,211	20,538	30,897	30,524	31,088	32,784	35,802	36,686	38,603	47,664
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	21,526	21,211	20,538	30,897	30,524	31,088	32,784	35,802	36,686	38,603	47,664
Common Stock	12,383	12,734	13,027	23,206	23,512	23,853	24,145	24,470	24,709	24,869	25,153
Retained Earnings	22,874	25,757	25,565	23,978	24,560	25,847	27,627	31,528	35,257	37,554	47,261
Accumulated Other Comprehensive Income / (Loss)	-5,053	-6,658	-7,263	-6,062	-7,586	-8,465	-8,946	-8,374	-8,051	-7,839	-7,906
Other Equity Adjustments	-	-	-	-	-9,962	-	-	-11,822	-15,229	-15,981	-16,844
Noncontrolling Interest	113	115	179	201	198	213	219	222	219	224	237

This table presents Abbott Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Total Assets	74,438	73,794	73,354	72,090	73,214	72,467	73,017	74,356	81,414	81,448	83,999
Total Current Assets	25,224	24,377	23,505	22,664	22,670	22,376	23,119	23,802	23,656	23,153	24,468
Cash & Equivalents	9,882	9,161	7,835	6,709	6,896	6,284	6,987	7,558	7,616	6,532	6,951
Short-Term Investments	288	371	320	338	383	367	232	230	351	312	331
Accounts Receivable	6,218	6,020	6,172	6,499	6,565	6,605	6,854	7,051	6,925	7,327	7,972
Inventories, net	6,173	6,673	6,871	6,650	6,570	6,827	6,814	6,813	6,194	6,639	6,954
Prepaid Expenses	2,663	2,152	2,307	2,468	2,256	2,293	2,232	2,150	2,570	2,343	2,260
Plant, Property, & Equipment, net	9,162	9,282	9,449	9,552	10,154	10,107	10,233	10,621	10,658	10,932	11,395
Plant, Property & Equipment, gross	20,212	20,605	20,926	21,111	21,933	22,055	22,061	22,857	22,740	23,418	24,472
Accumulated Depreciation	11,050	11,323	11,477	11,559	11,779	11,948	11,828	12,236	12,082	12,486	13,077
Total Noncurrent Assets	40,052	40,135	40,400	39,874	40,390	39,984	39,665	39,933	47,100	47,363	48,136
Long-Term Investments	766	776	799	788	799	818	877	912	886	907	958
Goodwill	22,799	22,927	23,258	23,277	23,679	23,383	23,308	23,658	23,108	23,359	23,952
Intangible Assets	10,454	10,006	9,834	9,282	8,815	8,296	7,827	7,352	6,647	6,261	5,920
Noncurrent Deferred & Refundable Income Taxes	6,033	6,426	6,509	6,527	7,097	7,487	7,653	8,011	16,459	16,836	17,306
Total Liabilities & Shareholders' Equity	74,438	73,794	73,354	72,090	73,214	72,467	73,017	74,356	81,414	81,448	83,999
Total Liabilities	37,533	36,562	35,950	34,396	34,387	33,424	33,457	34,328	33,513	32,384	33,170
Total Current Liabilities	15,489	14,530	14,350	13,042	13,841	14,021	13,760	14,902	14,157	13,004	13,439
Short-Term Debt	2,251	2,285	2,284	1,051	1,080	2,010	1,615	2,154	1,500	506	507
Accounts Payable	4,607	4,167	4,211	3,961	4,295	4,178	4,125	4,034	4,195	4,214	4,306
Accrued Expenses	5,845	5,758	5,334	5,347	5,422	5,220	5,071	5,427	5,143	5,600	5,656
Dividends Payable	887	888	886	886	955	959	959	956	1,024	1,032	1,030
Current Deferred & Payable Income Tax Liabilities	343	334	273	318	492	562	601	713	594	485	390
Current Employee Benefit Liabilities	1,556	1,098	1,362	1,479	1,597	1,092	1,389	1,618	1,701	1,167	1,550
Total Noncurrent Liabilities	22,044	22,032	21,600	21,354	20,546	19,403	19,697	19,426	19,356	19,380	19,731
Long-Term Debt	14,522	14,615	14,562	14,477	13,599	12,576	13,139	12,825	12,625	12,736	12,930
Noncurrent Deferred & Payable Income Tax Liabilities	-	7,417	7,038	6,877	-	6,827	6,558	6,601	-	6,644	6,801
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	36,905	37,232	37,404	37,694	38,827	39,043	39,560	40,028	47,901	49,064	50,829
Total Preferred & Common Equity	36,686	37,010	37,174	37,481	38,603	38,810	39,318	39,796	47,664	48,811	50,565
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	36,686	37,010	37,174	37,481	38,603	38,810	39,318	39,796	47,664	48,811	50,565
Common Stock	24,709	24,488	24,612	24,727	24,869	24,726	24,858	25,020	25,153	25,125	25,284
Retained Earnings	35,257	35,868	36,355	36,920	37,554	38,011	38,354	39,056	47,261	47,715	48,467
Accumulated Other Comprehensive Income / (Loss)	-8,051	-8,039	-8,071	-8,480	-7,839	-8,166	-8,135	-7,804	-7,906	-7,417	-6,576
Other Equity Adjustments	-15,229	-	-	-	-15,981	-15,761	-	-	-	-	-16,610
Noncontrolling Interest	219	222	230	213	224	233	242	232	237	253	264

This table displays calculated financial ratios and metrics derived from Abbott Laboratories' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.00%	0.78%	2.20%	31.35%	11.64%	4.34%	8.48%	24.47%	1.34%	-8.12%	4.59%
EBITDA Growth	8.31%	13.38%	-30.77%	112.81%	1.83%	9.32%	13.78%	39.16%	-2.38%	-14.97%	2.83%
EBIT Growth	23.12%	24.22%	-46.16%	72.55%	24.91%	25.39%	15.95%	59.13%	-0.23%	-20.33%	4.51%
NOPAT Growth	-14.50%	32.14%	-3.02%	-89.13%	1,098.25%	38.22%	17.63%	50.49%	-3.80%	-20.29%	134.44%
Net Income Growth	-11.34%	93.65%	-68.35%	-65.93%	396.44%	55.70%	21.91%	57.31%	-1.95%	-17.45%	134.18%
EPS Growth	-8.02%	95.97%	-67.81%	-71.28%	392.59%	54.89%	21.36%	57.60%	-0.76%	-16.62%	134.36%
Operating Cash Flow Growth	10.56%	-19.29%	7.99%	73.90%	13.11%	-2.60%	28.76%	33.31%	-9.04%	-24.21%	17.86%
Free Cash Flow Firm Growth	-75.60%	84.66%	0.33%	-747.37%	119.64%	-16.97%	7.72%	51.00%	-10.05%	-60.93%	86.12%
Invested Capital Growth	-3.09%	-9.93%	-11.44%	164.91%	-6.05%	-1.78%	-1.05%	-1.66%	-0.48%	6.31%	16.85%
Revenue Q/Q Growth	6.99%	-0.70%	0.70%	8.98%	0.58%	1.75%	7.41%	1.81%	-3.06%	0.38%	1.78%
EBITDA Q/Q Growth	10.47%	-0.59%	9.50%	3.15%	3.63%	3.34%	15.54%	-0.42%	-8.69%	5.01%	1.99%
EBIT Q/Q Growth	19.46%	0.03%	10.44%	-6.78%	11.90%	5.76%	24.41%	-0.78%	-10.89%	7.44%	2.99%
NOPAT Q/Q Growth	21.76%	1.16%	2.76%	-81.43%	190.04%	9.32%	26.98%	-2.24%	-12.68%	11.13%	129.00%
Net Income Q/Q Growth	16.00%	-3.03%	2.26%	-77.32%	167.27%	12.00%	32.91%	-2.39%	-12.12%	10.87%	132.39%
EPS Q/Q Growth	13.74%	-4.26%	3.30%	-78.91%	171.43%	11.96%	32.28%	-2.23%	-11.74%	10.88%	132.22%
Operating Cash Flow Q/Q Growth	-9.53%	-12.14%	11.95%	9.22%	2.02%	11.87%	21.20%	-6.49%	-7.18%	10.87%	-1.95%
Free Cash Flow Firm Q/Q Growth	387.49%	-82.50%	126.77%	-30.39%	551.28%	32.18%	6.70%	-14.56%	-18.97%	138.07%	11.12%
Invested Capital Q/Q Growth	-4.54%	0.00%	-6.03%	10.80%	-1.14%	-2.96%	-1.51%	1.18%	2.78%	0.24%	14.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.47%	57.13%	56.39%	54.70%	58.45%	58.53%	56.65%	56.97%	56.15%	55.18%	55.41%
EBITDA Margin	20.53%	23.10%	15.65%	25.35%	23.12%	24.23%	25.41%	28.41%	27.37%	25.33%	24.90%
Operating Margin	12.84%	14.05%	14.51%	5.71%	11.94%	14.21%	15.48%	19.56%	19.16%	16.15%	16.27%
EBIT Margin	12.89%	15.88%	8.37%	10.99%	12.30%	14.78%	15.80%	20.20%	19.89%	17.24%	17.23%
Profit (Net Income) Margin	11.28%	21.68%	6.71%	1.74%	7.74%	11.56%	12.99%	16.42%	15.88%	14.27%	31.95%
Tax Burden Percent	90.71%	138.96%	99.08%	21.38%	82.42%	90.43%	90.48%	86.12%	83.47%	85.88%	191.10%
Interest Burden Percent	96.51%	98.21%	80.97%	74.10%	76.39%	86.45%	90.86%	94.37%	95.68%	96.36%	97.03%
Effective Tax Rate	31.65%	18.13%	24.77%	84.18%	18.76%	9.57%	10.00%	13.88%	16.53%	14.12%	-91.10%
Return on Invested Capital (ROIC)	7.57%	10.69%	11.60%	0.74%	6.26%	9.02%	10.76%	16.41%	15.96%	12.36%	25.94%
ROIC Less NNEP Spread (ROIC-NNEP)	2,610.84%	448.14%	74.14%	3.71%	2.63%	6.17%	8.18%	14.51%	15.32%	14.60%	31.12%
Return on Net Nonoperating Assets (RNNOA)	2.17%	9.90%	-4.94%	1.11%	1.40%	2.87%	3.22%	4.08%	3.05%	2.75%	4.97%
Return on Equity (ROE)	9.74%	20.59%	6.66%	1.84%	7.66%	11.89%	13.98%	20.49%	19.01%	15.11%	30.91%
Cash Return on Invested Capital (CROIC)	10.71%	21.14%	23.73%	-89.65%	12.50%	10.81%	11.81%	18.08%	16.44%	6.24%	10.40%
Operating Return on Assets (OROA)	6.20%	7.86%	3.72%	4.67%	5.24%	6.98%	7.79%	11.78%	11.60%	9.37%	9.35%
Return on Assets (ROA)	5.43%	10.73%	2.98%	0.74%	3.30%	5.46%	6.40%	9.57%	9.27%	7.75%	17.33%
Return on Common Equity (ROCE)	9.70%	20.48%	6.61%	1.83%	7.61%	11.81%	13.89%	20.36%	18.90%	15.03%	30.74%
Return on Equity Simple (ROE_SIMPLE)	10.61%	20.85%	6.82%	1.54%	7.76%	11.86%	13.71%	19.75%	18.90%	14.83%	28.12%
Net Operating Profit after Tax (NOPAT)	1,776	2,347	2,276	247	2,965	4,098	4,821	7,255	6,980	5,563	13,043
NOPAT Margin	8.77%	11.50%	10.92%	0.90%	9.70%	12.85%	13.93%	16.84%	15.99%	13.87%	31.09%
Net Nonoperating Expense Percent (NNEP)	-2,603.27%	-437.45%	-62.54%	-2.97%	3.63%	2.85%	2.58%	1.90%	0.64%	-2.24%	-5.19%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	13.00%	10.40%	21.03%
Cost of Revenue to Revenue	45.53%	42.87%	43.61%	45.30%	41.55%	41.47%	43.35%	43.03%	43.85%	44.82%	44.59%
SG&A Expenses to Revenue	32.25%	33.25%	32.30%	33.52%	31.87%	36.68%	28.02%	26.29%	25.77%	27.30%	27.88%
R&D to Revenue	6.64%	6.89%	6.94%	8.25%	7.52%	7.65%	6.99%	6.37%	6.62%	6.83%	6.78%
Operating Expenses to Revenue	41.64%	43.08%	41.88%	48.99%	46.51%	44.32%	41.17%	37.41%	36.99%	39.03%	39.14%
Earnings before Interest and Taxes (EBIT)	2,609	3,241	1,745	3,011	3,761	4,716	5,468	8,701	8,681	6,916	7,228
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4,157	4,713	3,263	6,944	7,071	7,730	8,795	12,239	11,948	10,159	10,446
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.62	2.68	2.39	2.86	3.77	4.55	5.54	6.60	4.99	4.83	4.09
Price to Tangible Book Value (P/TBV)	10.70	9.44	5.91	0.00	0.00	0.00	0.00	0.00	53.32	30.51	10.90
Price to Revenue (P/Rev)	2.78	2.78	2.36	3.23	3.76	4.43	5.24	5.49	4.19	4.65	4.65
Price to Earnings (P/E)	24.65	12.83	35.12	185.24	48.59	38.36	40.38	33.43	26.40	32.57	14.56
Dividend Yield	2.35%	2.52%	3.11%	2.09%	1.71%	1.60%	1.41%	1.35%	1.79%	1.90%	1.96%
Earnings Yield	4.06%	7.79%	2.85%	0.54%	2.06%	2.61%	2.48%	2.99%	3.79%	3.07%	6.87%
Enterprise Value to Invested Capital (EV/IC)	2.58	2.68	2.69	2.17	2.83	3.44	4.32	5.56	4.33	4.17	3.70
Enterprise Value to Revenue (EV/Rev)	2.94	2.73	2.38	3.87	4.25	4.85	5.56	5.65	4.33	4.82	4.78
Enterprise Value to EBITDA (EV/EBITDA)	14.32	11.82	15.21	15.26	18.36	20.02	21.89	19.90	15.83	19.02	19.21
Enterprise Value to EBIT (EV/EBIT)	22.82	17.19	28.44	35.20	34.53	32.82	35.21	27.99	21.78	27.93	27.76
Enterprise Value to NOPAT (EV/NOPAT)	33.52	23.73	21.80	428.31	43.79	37.76	39.93	33.57	27.09	34.73	15.39
Enterprise Value to Operating Cash Flow (EV/OCF)	16.20	18.78	15.49	19.03	20.61	25.22	24.36	23.13	19.74	26.61	23.45
Enterprise Value to Free Cash Flow (EV/FCFF)	23.69	12.00	10.66	0.00	21.94	31.49	36.36	30.47	26.30	68.77	38.38
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.36	0.42	1.06	0.90	0.64	0.58	0.57	0.50	0.45	0.38	0.29
Long-Term Debt to Equity	0.16	0.28	1.00	0.88	0.63	0.53	0.56	0.48	0.39	0.35	0.26
Financial Leverage	0.00	0.02	-0.07	0.30	0.53	0.47	0.39	0.28	0.20	0.19	0.16
Leverage Ratio	1.79	1.92	2.23	2.49	2.32	2.18	2.18	2.14	2.05	1.95	1.78
Compound Leverage Factor	1.73	1.88	1.81	1.84	1.77	1.88	1.98	2.02	1.96	1.88	1.73
Debt to Total Capital	26.57%	29.68%	51.51%	47.31%	38.91%	36.69%	36.23%	33.38%	31.25%	27.43%	22.77%
Short-Term Debt to Total Capital	15.06%	10.32%	3.10%	1.21%	0.41%	2.99%	0.43%	1.39%	4.19%	2.02%	2.42%
Long-Term Debt to Total Capital	11.51%	19.36%	48.41%	46.10%	38.50%	33.70%	35.80%	31.99%	27.05%	25.42%	20.35%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.38%	0.38%	0.42%	0.34%	0.39%	0.43%	0.42%	0.41%	0.41%	0.42%	0.38%
Common Equity to Total Capital	73.05%	69.94%	48.07%	52.35%	60.70%	62.88%	63.35%	66.21%	68.34%	72.15%	76.85%
Debt to EBITDA	1.88	1.91	6.74	4.02	2.77	2.35	2.13	1.47	1.40	1.44	1.35
Net Debt to EBITDA	0.76	-0.25	0.09	2.51	2.06	1.70	1.23	0.57	0.49	0.65	0.50
Long-Term Debt to EBITDA	0.82	1.25	6.34	3.92	2.74	2.16	2.11	1.41	1.22	1.34	1.21
Debt to NOPAT	4.41	3.83	9.67	112.84	6.60	4.43	3.89	2.49	2.40	2.64	1.08
Net Debt to NOPAT	1.77	-0.50	0.12	70.44	4.92	3.20	2.24	0.96	0.84	1.19	0.40
Long-Term Debt to NOPAT	1.91	2.50	9.08	109.96	6.53	4.07	3.84	2.38	2.08	2.44	0.97
Altman Z-Score	3.29	3.48	2.57	2.28	3.15	3.64	4.15	5.34	4.72	4.97	5.26
Noncontrolling Interest Sharing Ratio	0.45%	0.53%	0.70%	0.73%	0.65%	0.66%	0.67%	0.64%	0.60%	0.59%	0.53%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.30	1.54	4.02	2.26	1.62	1.44	1.72	1.85	1.63	1.64	1.67
Quick Ratio	0.77	1.04	3.31	1.67	1.03	0.88	1.14	1.28	1.06	1.00	1.05
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	2,513	4,641	4,656	-30,145	5,919	4,914	5,294	7,994	7,191	2,809	5,229
Operating Cash Flow to CapEx	341.23%	267.21%	285.73%	490.75%	451.94%	374.60%	362.93%	558.78%	539.17%	329.75%	387.77%
Free Cash Flow to Firm to Interest Expense	14.96	28.47	10.80	-33.35	5.96	6.70	9.70	15.00	12.89	4.41	9.35
Operating Cash Flow to Interest Expense	21.88	18.20	7.43	6.16	6.34	8.37	14.47	19.76	17.17	11.40	15.31
Operating Cash Flow Less CapEx to Interest Expense	15.46	11.39	4.83	4.91	4.94	6.14	10.48	16.23	13.99	7.94	11.36
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.48	0.49	0.44	0.42	0.43	0.47	0.49	0.58	0.58	0.54	0.54
Accounts Receivable Turnover	5.35	5.83	6.26	6.45	5.86	6.02	5.85	6.68	6.87	6.28	6.22
Inventory Turnover	3.46	3.34	3.61	4.11	3.44	3.26	3.22	3.65	3.38	2.82	2.93
Fixed Asset Turnover	3.42	3.50	3.65	4.12	4.03	4.09	4.06	4.79	4.82	4.15	4.03
Accounts Payable Turnover	8.82	8.16	8.05	6.93	4.73	4.25	4.17	4.44	4.25	4.04	4.41
Days Sales Outstanding (DSO)	68.25	62.64	58.34	56.62	62.26	60.68	62.43	54.66	53.12	58.16	58.69
Days Inventory Outstanding (DIO)	105.64	109.37	101.00	88.76	106.25	111.89	113.47	100.12	108.02	129.38	124.53
Days Payable Outstanding (DPO)	41.38	44.75	45.33	52.65	77.23	85.89	87.56	82.25	85.95	90.38	82.83
Cash Conversion Cycle (CCC)	132.52	127.26	114.01	92.72	91.27	86.68	88.34	72.53	75.19	97.16	100.39
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	23,104	20,810	18,430	48,822	45,868	45,052	44,579	43,840	43,629	46,383	54,197
Invested Capital Turnover	0.86	0.93	1.06	0.81	0.65	0.70	0.77	0.97	1.00	0.89	0.83
Increase / (Decrease) in Invested Capital	-737	-2,294	-2,380	30,392	-2,954	-816	-473	-739	-211	2,754	7,814
Enterprise Value (EV)	59,545	55,710	49,625	105,991	129,850	154,775	192,505	243,582	189,096	193,196	200,669
Market Capitalization	56,291	56,760	49,162	88,359	115,069	141,446	181,508	236,375	183,040	186,371	195,160
Book Value per Share	$14.30	$14.18	$13.95	$17.75	$17.38	$17.58	$18.50	$20.25	$21.04	$22.24	$27.48
Tangible Book Value per Share	$3.49	$4.02	$5.65	($8.39)	($6.65)	($5.16)	($3.24)	($0.10)	$1.97	$3.52	$10.33
Total Capital	29,469	30,327	42,723	59,022	50,288	49,440	51,750	54,074	53,678	53,506	62,026
Total Debt	7,830	9,001	22,006	27,924	19,566	18,139	18,747	18,050	16,773	14,679	14,125
Total Long-Term Debt	3,393	5,871	20,681	27,210	19,359	16,661	18,527	17,296	14,522	13,599	12,625
Net Debt	3,141	-1,165	284	17,431	14,583	13,116	10,778	6,985	5,837	6,601	5,272
Capital Expenditures (CapEx)	1,077	1,110	1,121	1,135	1,394	1,638	2,177	1,885	1,777	2,202	2,207
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3,066	1,974	2,666	2,339	1,741	2,142	1,606	1,639	1,816	2,630	3,032
Debt-free Net Working Capital (DFNWC)	7,526	8,099	21,441	11,949	5,827	6,282	8,754	11,888	11,986	9,909	10,999
Net Working Capital (NWC)	3,089	4,969	20,116	11,235	5,620	4,804	8,534	11,134	9,735	8,829	9,499
Net Nonoperating Expense (NNE)	-508	-2,076	876	-230	597	411	326	184	47	-160	-359
Net Nonoperating Obligations (NNO)	1,465	-516	-2,287	17,724	15,146	13,751	11,576	7,816	6,724	7,556	6,296
Total Depreciation and Amortization (D&A)	1,548	1,472	1,518	3,933	3,310	3,014	3,327	3,538	3,267	3,243	3,218
Debt-free, Cash-free Net Working Capital to Revenue	15.14%	9.67%	12.78%	8.54%	5.69%	6.71%	4.64%	3.81%	4.16%	6.56%	7.23%
Debt-free Net Working Capital to Revenue	37.17%	39.69%	102.82%	43.63%	19.06%	19.69%	25.29%	27.60%	27.46%	24.71%	26.22%
Net Working Capital to Revenue	15.26%	24.35%	96.47%	41.02%	18.38%	15.06%	24.66%	25.85%	22.30%	22.01%	22.64%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.50	$2.94	$0.94	$0.27	$1.34	$2.07	$2.52	$3.97	$3.94	$3.28	$7.67
Adjusted Weighted Average Basic Shares Outstanding	1.52B	1.50B	1.48B	1.74B	1.76B	1.77B	1.77B	1.78B	1.75B	1.74B	1.74B
Adjusted Diluted Earnings per Share	$1.49	$2.92	$0.94	$0.27	$1.33	$2.06	$2.50	$3.94	$3.91	$3.26	$7.64
Adjusted Weighted Average Diluted Shares Outstanding	1.53B	1.51B	1.48B	1.75B	1.77B	1.78B	1.79B	1.79B	1.76B	1.75B	1.75B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$2.07	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.51B	1.47B	1.73B	1.75B	1.76B	1.76B	1.77B	1.76B	1.74B	1.74B	1.73B
Normalized Net Operating Profit after Tax (NOPAT)	1,776	2,347	2,276	1,095	2,965	4,098	4,821	7,255	6,980	5,563	4,778
Normalized NOPAT Margin	8.77%	11.50%	10.92%	4.00%	9.70%	12.85%	13.93%	16.84%	15.99%	13.87%	11.39%
Pre Tax Income Margin	12.44%	15.60%	6.78%	8.15%	9.40%	12.78%	14.36%	19.06%	19.03%	16.61%	16.72%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	15.53	19.88	4.05	3.33	3.79	6.43	10.01	16.32	15.56	10.86	12.93
NOPAT to Interest Expense	10.57	14.40	5.28	0.27	2.99	5.59	8.83	13.61	12.51	8.73	23.33
EBIT Less CapEx to Interest Expense	9.12	13.07	1.45	2.08	2.38	4.20	6.03	12.79	12.37	7.40	8.98
NOPAT Less CapEx to Interest Expense	4.16	7.59	2.68	-0.98	1.58	3.36	4.84	10.08	9.32	5.28	19.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	58.76%	32.62%	109.93%	387.63%	83.36%	61.57%	56.95%	45.28%	47.73%	62.14%	28.62%
Augmented Payout Ratio	154.86%	83.20%	147.21%	412.16%	93.41%	81.04%	65.92%	77.80%	102.47%	83.58%	38.29%

This table displays calculated financial ratios and metrics derived from Abbott Laboratories' official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-12.01%	-18.06%	-11.36%	-2.56%	1.49%	2.23%	4.00%	4.85%	7.16%	3.95%	7.37%
EBITDA Growth	-34.14%	-36.58%	-23.87%	-3.57%	22.12%	-4.88%	-1.08%	8.89%	7.62%	12.21%	20.53%
EBIT Growth	-43.36%	-46.07%	-30.96%	-5.64%	34.56%	-7.25%	-1.89%	14.43%	11.26%	22.04%	32.13%
NOPAT Growth	-49.79%	-48.61%	-36.43%	-2.04%	54.90%	-7.14%	4.34%	11.44%	449.64%	6.71%	25.56%
Net Income Growth	-48.06%	-46.14%	-31.86%	0.07%	54.31%	-7.06%	-5.31%	14.62%	478.98%	8.16%	36.64%
EPS Growth	-46.85%	-45.26%	-31.58%	1.23%	54.24%	-6.67%	-5.13%	14.63%	478.02%	8.57%	36.49%
Operating Cash Flow Growth	-24.16%	-44.65%	-50.08%	-32.48%	30.61%	-10.32%	62.93%	44.11%	-5.60%	38.24%	4.44%
Free Cash Flow Firm Growth	-55.57%	-29.76%	-145.43%	-203.65%	-195.28%	-203.50%	158.56%	124.36%	174.49%	-488.44%	-2,390.13%
Invested Capital Growth	-0.48%	0.20%	4.30%	9.01%	6.31%	5.38%	2.15%	2.14%	16.85%	17.97%	20.94%
Revenue Q/Q Growth	-3.06%	-3.41%	2.37%	1.65%	0.97%	-2.70%	4.14%	2.49%	3.19%	-5.61%	7.57%
EBITDA Q/Q Growth	-17.53%	10.35%	3.18%	2.68%	4.45%	-14.04%	7.30%	13.04%	3.22%	-10.37%	15.25%
EBIT Q/Q Growth	-24.84%	16.45%	5.14%	2.53%	7.18%	-19.73%	11.22%	19.58%	4.22%	-11.95%	20.42%
NOPAT Q/Q Growth	-29.37%	24.77%	1.78%	9.21%	11.68%	-25.20%	14.37%	16.64%	450.82%	-85.48%	34.58%
Net Income Q/Q Growth	-28.01%	27.59%	4.32%	4.44%	11.00%	-23.15%	6.29%	26.42%	460.69%	-85.64%	34.26%
EPS Q/Q Growth	-27.16%	27.12%	4.00%	5.13%	10.98%	-23.08%	5.71%	27.03%	459.57%	-85.55%	32.89%
Operating Cash Flow Q/Q Growth	-16.33%	-50.86%	5.25%	56.03%	61.85%	-66.26%	91.22%	38.01%	6.03%	-50.59%	44.46%
Free Cash Flow Firm Q/Q Growth	-47.05%	-3.91%	-151.55%	-295.18%	51.33%	-4.38%	129.17%	64.40%	48.82%	-924.53%	-13.53%
Invested Capital Q/Q Growth	2.78%	2.48%	3.29%	0.20%	0.24%	1.59%	0.12%	0.18%	14.67%	2.56%	2.64%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.48%	55.57%	55.07%	54.60%	55.51%	55.21%	55.64%	55.83%	54.97%	56.86%	56.44%
EBITDA Margin	21.73%	24.83%	25.03%	25.28%	26.15%	23.10%	23.80%	26.25%	26.26%	24.94%	26.72%
Operating Margin	12.92%	15.48%	15.45%	16.24%	17.38%	13.91%	16.08%	17.48%	17.41%	16.34%	18.42%
EBIT Margin	13.74%	16.56%	17.01%	17.15%	18.21%	15.02%	16.05%	18.72%	18.91%	17.64%	19.75%
Profit (Net Income) Margin	10.24%	13.52%	13.78%	14.16%	15.56%	12.29%	12.55%	15.48%	84.10%	12.79%	15.97%
Tax Burden Percent	78.26%	84.38%	84.05%	85.94%	88.80%	85.31%	81.02%	84.85%	454.63%	74.52%	82.74%
Interest Burden Percent	95.24%	96.78%	96.41%	96.03%	96.25%	95.93%	96.52%	97.44%	97.83%	97.32%	97.73%
Effective Tax Rate	21.74%	15.62%	15.95%	14.06%	11.20%	14.69%	18.98%	15.15%	-354.63%	25.48%	17.26%
Return on Invested Capital (ROIC)	10.09%	12.14%	11.55%	12.57%	13.76%	10.42%	11.37%	13.07%	66.04%	10.04%	12.61%
ROIC Less NNEP Spread (ROIC-NNEP)	10.27%	12.68%	12.52%	12.84%	13.94%	10.97%	10.76%	13.94%	73.85%	10.91%	13.78%
Return on Net Nonoperating Assets (RNNOA)	2.05%	2.87%	2.76%	2.64%	2.63%	2.24%	2.29%	2.84%	11.80%	1.81%	2.11%
Return on Equity (ROE)	12.14%	15.01%	14.31%	15.21%	16.38%	12.66%	13.66%	15.91%	77.83%	11.85%	14.72%
Cash Return on Invested Capital (CROIC)	16.44%	12.73%	6.92%	2.66%	6.24%	6.68%	9.72%	10.06%	10.40%	9.01%	6.57%
Operating Return on Assets (OROA)	8.01%	9.30%	9.27%	9.46%	9.89%	8.28%	8.93%	10.54%	10.26%	9.71%	10.84%
Return on Assets (ROA)	5.97%	7.59%	7.51%	7.81%	8.46%	6.78%	6.98%	8.71%	45.63%	7.04%	8.77%
Return on Common Equity (ROCE)	12.07%	14.91%	14.22%	15.13%	16.29%	12.58%	13.58%	15.82%	77.42%	11.79%	14.63%
Return on Equity Simple (ROE_SIMPLE)	0.00%	15.68%	13.88%	13.77%	0.00%	14.51%	14.13%	14.49%	0.00%	27.66%	0.00%
Net Operating Profit after Tax (NOPAT)	1,020	1,273	1,296	1,415	1,581	1,182	1,352	1,577	8,688	1,262	1,698
NOPAT Margin	10.11%	13.06%	12.99%	13.95%	15.43%	11.87%	13.03%	14.83%	79.17%	12.18%	15.24%
Net Nonoperating Expense Percent (NNEP)	-0.17%	-0.54%	-0.97%	-0.27%	-0.19%	-0.55%	0.61%	-0.87%	-7.81%	-0.87%	-1.17%
Return On Investment Capital (ROIC_SIMPLE)	1.90%	-	-	-	2.95%	-	-	-	14.01%	2.02%	2.64%
Cost of Revenue to Revenue	45.52%	44.43%	44.93%	45.40%	44.49%	44.79%	44.36%	44.17%	45.03%	43.14%	43.56%
SG&A Expenses to Revenue	29.46%	28.34%	27.46%	26.85%	26.60%	29.70%	28.29%	27.22%	26.49%	29.55%	27.74%
R&D to Revenue	7.18%	6.71%	7.17%	6.63%	6.84%	6.86%	6.73%	6.70%	6.83%	6.91%	6.51%
Operating Expenses to Revenue	41.56%	40.08%	39.62%	38.36%	38.13%	41.30%	39.56%	38.35%	37.55%	40.52%	38.02%
Earnings before Interest and Taxes (EBIT)	1,386	1,614	1,697	1,740	1,865	1,497	1,665	1,991	2,075	1,827	2,200
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2,193	2,420	2,497	2,564	2,678	2,302	2,470	2,792	2,882	2,583	2,977
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.99	4.61	4.97	4.37	4.83	5.03	4.57	4.96	4.09	4.69	4.66
Price to Tangible Book Value (P/TBV)	53.32	41.87	45.28	33.29	30.51	27.39	21.97	22.47	10.90	11.93	11.38
Price to Revenue (P/Rev)	4.19	4.11	4.59	4.10	4.65	4.84	4.42	4.79	4.65	5.41	5.46
Price to Earnings (P/E)	26.40	29.41	35.81	31.75	32.57	34.69	32.36	34.24	14.56	16.96	16.85
Dividend Yield	1.79%	1.95%	1.84%	2.12%	1.90%	1.85%	2.05%	1.90%	1.96%	1.70%	1.68%
Earnings Yield	3.79%	3.40%	2.79%	3.15%	3.07%	2.88%	3.09%	2.92%	6.87%	5.90%	5.93%
Enterprise Value to Invested Capital (EV/IC)	4.33	3.97	4.18	3.71	4.17	4.30	3.96	4.32	3.70	4.22	4.22
Enterprise Value to Revenue (EV/Rev)	4.33	4.28	4.80	4.30	4.82	5.03	4.58	4.95	4.78	5.54	5.59
Enterprise Value to EBITDA (EV/EBITDA)	15.83	16.83	19.75	17.76	19.02	20.18	18.65	19.91	19.21	21.88	21.46
Enterprise Value to EBIT (EV/EBIT)	21.78	24.31	29.50	26.69	27.93	29.81	27.59	29.06	27.76	31.06	29.78
Enterprise Value to NOPAT (EV/NOPAT)	27.09	30.73	38.31	34.31	34.73	37.03	33.74	35.81	15.39	17.93	18.12
Enterprise Value to Operating Cash Flow (EV/OCF)	19.74	20.50	25.89	26.23	26.61	28.37	23.63	23.37	23.45	26.23	26.67
Enterprise Value to Free Cash Flow (EV/FCFF)	26.30	31.22	61.63	145.57	68.77	66.11	41.14	43.34	38.38	50.76	70.44
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.45	0.45	0.45	0.41	0.38	0.37	0.37	0.37	0.29	0.27	0.26
Long-Term Debt to Equity	0.39	0.39	0.39	0.38	0.35	0.32	0.33	0.32	0.26	0.26	0.25
Financial Leverage	0.20	0.23	0.22	0.21	0.19	0.20	0.21	0.20	0.16	0.17	0.15
Leverage Ratio	2.05	2.03	1.99	1.97	1.95	1.92	1.90	1.88	1.78	1.75	1.74
Compound Leverage Factor	1.95	1.96	1.92	1.89	1.88	1.84	1.84	1.84	1.74	1.70	1.70
Debt to Total Capital	31.25%	31.22%	31.05%	29.18%	27.43%	27.20%	27.16%	27.23%	22.77%	21.25%	20.91%
Short-Term Debt to Total Capital	4.19%	4.22%	4.21%	1.97%	2.02%	3.75%	2.97%	3.92%	2.42%	0.81%	0.79%
Long-Term Debt to Total Capital	27.05%	27.00%	26.84%	27.20%	25.42%	23.45%	24.19%	23.32%	20.35%	20.44%	20.12%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.41%	0.41%	0.42%	0.40%	0.42%	0.43%	0.45%	0.42%	0.38%	0.41%	0.41%
Common Equity to Total Capital	68.34%	68.37%	68.52%	70.42%	72.15%	72.37%	72.39%	72.35%	76.85%	78.34%	78.68%
Debt to EBITDA	1.40	1.60	1.72	1.61	1.44	1.45	1.47	1.46	1.35	1.23	1.20
Net Debt to EBITDA	0.49	0.62	0.81	0.80	0.65	0.71	0.66	0.61	0.50	0.51	0.46
Long-Term Debt to EBITDA	1.22	1.39	1.49	1.50	1.34	1.25	1.31	1.25	1.21	1.19	1.15
Debt to NOPAT	2.40	2.93	3.34	3.10	2.64	2.67	2.67	2.63	1.08	1.01	1.01
Net Debt to NOPAT	0.84	1.14	1.57	1.54	1.19	1.30	1.20	1.10	0.40	0.42	0.39
Long-Term Debt to NOPAT	2.08	2.53	2.89	2.89	2.44	2.30	2.37	2.25	0.97	0.97	0.97
Altman Z-Score	4.39	4.28	4.55	4.37	4.75	5.00	4.75	4.97	5.05	5.81	5.83
Noncontrolling Interest Sharing Ratio	0.60%	0.62%	0.62%	0.57%	0.59%	0.60%	0.61%	0.57%	0.53%	0.55%	0.56%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.63	1.68	1.64	1.74	1.64	1.60	1.68	1.60	1.67	1.78	1.82
Quick Ratio	1.06	1.07	1.00	1.04	1.00	0.95	1.02	1.00	1.05	1.09	1.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,231	1,183	-610	-2,411	-1,173	-1,225	357	587	874	-7,206	-8,181
Operating Cash Flow to CapEx	381.31%	300.79%	237.28%	335.18%	402.38%	257.54%	367.73%	486.51%	398.33%	292.77%	407.77%
Free Cash Flow to Firm to Interest Expense	8.00	7.73	-3.84	-14.52	-7.38	-8.69	2.55	4.14	6.43	-55.01	-67.61
Operating Cash Flow to Interest Expense	15.10	7.47	7.57	11.31	19.11	7.27	14.00	19.05	21.09	10.82	16.92
Operating Cash Flow Less CapEx to Interest Expense	11.14	4.99	4.38	7.93	14.36	4.45	10.19	15.13	15.79	7.12	12.77
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.58	0.56	0.55	0.55	0.54	0.55	0.56	0.56	0.54	0.55	0.55
Accounts Receivable Turnover	6.87	6.29	6.02	6.19	6.28	6.39	6.25	6.08	6.22	6.08	5.82
Inventory Turnover	3.38	2.99	2.82	2.91	2.82	2.68	2.66	2.72	2.93	2.78	2.75
Fixed Asset Turnover	4.82	4.56	4.40	4.38	4.15	4.16	4.14	4.09	4.03	4.03	3.99
Accounts Payable Turnover	4.25	4.14	4.14	4.45	4.04	4.34	4.37	4.58	4.41	4.46	4.50
Days Sales Outstanding (DSO)	53.12	58.04	60.66	58.95	58.16	57.14	58.37	60.00	58.69	60.05	62.77
Days Inventory Outstanding (DIO)	108.02	122.06	129.22	125.48	129.38	136.07	137.02	134.12	124.53	131.34	132.51
Days Payable Outstanding (DPO)	85.95	88.10	88.07	82.01	90.38	84.11	83.47	79.64	82.83	81.85	81.14
Cash Conversion Cycle (CCC)	75.19	92.00	101.80	102.42	97.16	109.09	111.93	114.47	100.39	109.54	114.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	43,629	44,712	46,182	46,273	46,383	47,119	47,177	47,263	54,197	55,587	57,056
Invested Capital Turnover	1.00	0.93	0.89	0.90	0.89	0.88	0.87	0.88	0.83	0.82	0.83
Increase / (Decrease) in Invested Capital	-211	90	1,906	3,826	2,754	2,407	995	990	7,814	8,468	9,879
Enterprise Value (EV)	189,096	177,538	192,954	171,780	193,196	202,660	186,711	203,946	200,669	234,741	241,039
Market Capitalization	183,040	170,724	184,832	163,874	186,371	195,310	179,811	197,435	195,160	228,997	235,578
Book Value per Share	$21.04	$21.30	$21.38	$21.60	$22.24	$22.30	$22.60	$22.87	$27.48	$28.14	$29.06
Tangible Book Value per Share	$1.97	$2.35	$2.35	$2.84	$3.52	$4.10	$4.70	$5.05	$10.33	$11.07	$11.89
Total Capital	53,678	54,132	54,250	53,222	53,506	53,629	54,314	55,007	62,026	62,306	64,266
Total Debt	16,773	16,900	16,846	15,528	14,679	14,586	14,754	14,979	14,125	13,242	13,437
Total Long-Term Debt	14,522	14,615	14,562	14,477	13,599	12,576	13,139	12,825	12,625	12,736	12,930
Net Debt	5,837	6,592	7,892	7,693	6,601	7,117	6,658	6,279	5,272	5,491	5,197
Capital Expenditures (CapEx)	610	380	507	560	755	398	533	556	720	484	502
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,816	2,600	3,284	3,626	2,630	3,714	3,755	3,266	3,032	3,811	4,254
Debt-free Net Working Capital (DFNWC)	11,986	12,132	11,439	10,673	9,909	10,365	10,974	11,054	10,999	10,655	11,536
Net Working Capital (NWC)	9,735	9,847	9,155	9,622	8,829	8,355	9,359	8,900	9,499	10,149	11,029
Net Nonoperating Expense (NNE)	-13	-45	-79	-21	-13	-43	50	-69	-541	-63	-81
Net Nonoperating Obligations (NNO)	6,724	7,480	8,778	8,579	7,556	8,076	7,617	7,235	6,296	6,523	6,227
Total Depreciation and Amortization (D&A)	807	806	800	824	813	805	805	801	807	756	777
Debt-free, Cash-free Net Working Capital to Revenue	4.16%	6.26%	8.16%	9.07%	6.56%	9.21%	9.22%	7.92%	7.23%	9.00%	9.87%
Debt-free Net Working Capital to Revenue	27.46%	29.23%	28.44%	26.71%	24.71%	25.70%	26.95%	26.82%	26.22%	25.16%	26.76%
Net Working Capital to Revenue	22.30%	23.72%	22.76%	24.08%	22.01%	20.72%	22.98%	21.59%	22.64%	23.97%	25.58%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.59	$0.75	$0.79	$0.82	$0.92	$0.70	$0.74	$0.94	$5.29	$0.76	$1.02
Adjusted Weighted Average Basic Shares Outstanding	1.75B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B
Adjusted Diluted Earnings per Share	$0.59	$0.75	$0.78	$0.82	$0.91	$0.70	$0.74	$0.94	$5.26	$0.76	$1.01
Adjusted Weighted Average Diluted Shares Outstanding	1.76B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B	1.75B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.74B	1.73B	1.73B	1.74B	1.74B
Normalized Net Operating Profit after Tax (NOPAT)	1,020	1,273	1,296	1,415	1,581	1,182	1,352	1,577	1,338	1,262	1,698
Normalized NOPAT Margin	10.11%	13.06%	12.99%	13.95%	15.43%	11.87%	13.03%	14.83%	12.19%	12.18%	15.24%
Pre Tax Income Margin	13.08%	16.03%	16.40%	16.47%	17.53%	14.41%	15.49%	18.24%	18.50%	17.17%	19.30%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	9.00	10.55	10.67	10.48	11.73	10.62	11.89	14.02	15.26	13.95	18.18
NOPAT to Interest Expense	6.63	8.32	8.15	8.53	9.94	8.39	9.66	11.11	63.88	9.63	14.03
EBIT Less CapEx to Interest Expense	5.04	8.07	7.48	7.11	6.98	7.79	8.09	10.11	9.96	10.25	14.03
NOPAT Less CapEx to Interest Expense	2.67	5.84	4.96	5.15	5.19	5.56	5.85	7.19	58.59	5.94	9.88
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	47.73%	58.01%	66.44%	67.63%	62.14%	64.35%	66.47%	65.30%	28.62%	28.92%	28.42%
Augmented Payout Ratio	102.47%	92.95%	113.89%	99.65%	83.58%	80.57%	75.29%	86.79%	38.29%	38.91%	38.09%

Key Financial Trends

Abbott Laboratories (NYSE: ABT) has demonstrated steady financial performance over the last four years through Q2 2025, with some notable trends in revenue, profitability, liquidity, and capital allocation.

Revenue and Profitability:

Operating revenue increased from approximately $9.75 billion in Q1 2023 to $11.14 billion in Q2 2025, marking a consistent upward trend.
Net income improved from around $1.32 billion in Q1 2023 to about $1.78 billion in Q2 2025, indicating enhanced earnings capacity.
Gross profit margin remained strong, with gross profit growing from $5.4 billion in Q1 2023 to $6.29 billion in Q2 2025.
Selling, General & Administrative (SG&A) and Research & Development (R&D) expenses have increased moderately but remain proportional to revenue growth, supporting sustained investments in innovation and operations.
Basic and diluted earnings per share rose from $0.70 in Q1 2023 to $1.02 in Q2 2025, reflecting earnings growth alongside relatively stable share counts.

Cash Flow and Capital Spending:

Net cash from operating activities increased from approximately $1.03 billion in Q1 2023 to $2.05 billion in Q2 2025, suggesting robust cash generation improvements.
Despite growing cash from operations, capital expenditures for property, plant, and equipment have remained significant, around $400-500 million quarterly, indicating continuing investments but also high capital intensity.
Net cash used in financing activities (including debt repayments, dividends, and share repurchases) has consistently exceeded cash provided, signaling substantial cash outflows towards shareholder returns and debt reduction.

Balance Sheet and Liquidity:

Cash and equivalents grew from about $6.28 billion in Q1 2024 to $6.95 billion in Q2 2025, showing a solid liquidity position.
Total assets increased steadily, primarily driven by goodwill and intangible assets, which together represent a sizable portion of total assets (~$29B goodwill and ~$5.9B intangibles as of Q2 2025), reflecting acquisitions and intellectual property investments.
Long-term debt has fluctuated around $12.9 - $14.6 billion over recent quarters, indicating manageable leverage but the necessity to monitor interest obligations (interest expense around $120-160 million per quarter).
Total liabilities relative to equity yields a balanced capital structure, with total liabilities approximately $33.2 billion and total equity around $50.6 billion as of Q2 2025.

Dividend and Share Repurchases:

Abbott has maintained a consistent dividend payout of $0.59 per share in recent quarters, highlighting steady shareholder return.
However, repurchases of common equity have slowed down recently, from hundreds of millions in 2023 to smaller amounts in 2025, likely reflecting a cautious approach to capital distribution.

Summary:

Abbott Laboratories shows steady revenue and net income growth over the last four years.
Strong cash flow generation bolsters liquidity and supports dividend payments.
The company sustains significant investments in property, plant, equipment, and R&D aligning with long-term growth strategies.
Leverage remains moderate but requires attention given sizeable interest expenses.
Heavy cash outflows from financing activities could pressure liquidity if operational cash flow growth slows.

Overall, Abbott Labs maintains a solid financial footing with improving profitability and cash flows, tempered by ongoing capital expenditures and significant financing outflows for debt and shareholder returns. Investors may view the company's consistent revenue growth and strong cash generation as positive signals, though the capital intensity and leverage levels warrant monitoring.

08/23/25 11:22 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Abbott Laboratories' Financials

When does Abbott Laboratories' financial year end?

According to the most recent income statement we have on file, Abbott Laboratories' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Abbott Laboratories' net income changed over the last 10 years?

Abbott Laboratories' net income appears to be on an upward trend, with a most recent value of $13.40 billion in 2024, rising from $2.28 billion in 2014. The previous period was $5.72 billion in 2023. See where experts think Abbott Laboratories is headed by visiting Abbott Laboratories' forecast page.

What is Abbott Laboratories' operating income?

Abbott Laboratories' total operating income in 2024 was $6.83 billion, based on the following breakdown:

Total Gross Profit: $23.24 billion
Total Operating Expenses: $16.42 billion

How has Abbott Laboratories' revenue changed over the last 10 years?

Over the last 10 years, Abbott Laboratories' total revenue changed from $20.25 billion in 2014 to $41.95 billion in 2024, a change of 107.2%.

How much debt does Abbott Laboratories have?

Abbott Laboratories' total liabilities were at $33.51 billion at the end of 2024, a 2.5% decrease from 2023, and a 71.3% increase since 2014.

How much cash does Abbott Laboratories have?

In the past 10 years, Abbott Laboratories' cash and equivalents has ranged from $3.84 billion in 2018 to $18.62 billion in 2016, and is currently $7.62 billion as of their latest financial filing in 2024.

How has Abbott Laboratories' book value per share changed over the last 10 years?

Over the last 10 years, Abbott Laboratories' book value per share changed from 14.30 in 2014 to 27.48 in 2024, a change of 92.2%.

Related Companies

This page (NYSE:ABT) was last updated on 8/23/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Financials

Key Financial Trends

Frequently Asked Questions About Abbott Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abbott Laboratories (ABT) Financials

Annual Income Statements for Abbott Laboratories

Quarterly Income Statements for Abbott Laboratories

Annual Cash Flow Statements for Abbott Laboratories

Quarterly Cash Flow Statements for Abbott Laboratories

Annual Balance Sheets for Abbott Laboratories

Quarterly Balance Sheets for Abbott Laboratories

Annual Metrics And Ratios for Abbott Laboratories

Quarterly Metrics And Ratios for Abbott Laboratories

Key Financial Trends

Frequently Asked Questions About Abbott Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools